Xeris Biopharma HoldingsXERS
XERS
About: Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Employees: 394
0
Funds holding %
of 7,433 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
143% more call options, than puts
Call options by funds: $807K | Put options by funds: $332K
37% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 57
13% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 24
1.24% more ownership
Funds ownership: 56.39% [Q1] → 57.63% (+1.24%) [Q2]
1% less funds holding
Funds holding: 199 [Q1] → 198 (-1) [Q2]
12% less capital invested
Capital invested by funds: $477M [Q1] → $421M (-$55.7M) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
1%
upside
Avg. target
$9.50
20%
upside
High target
$11
39%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Leerink Partners Roanna Ruiz | 14%upside $9 | Outperform Maintained | 19 Aug 2025 |
HC Wainwright & Co. Brandon Folkes | 27%upside $10 | Buy Assumed | 12 Aug 2025 |
Craig-Hallum Chase Knickerbocker | 39%upside $11 | Buy Maintained | 8 Aug 2025 |
Oppenheimer Leland Gershell | 1%upside $8 | Outperform Maintained | 8 Aug 2025 |
Financial journalist opinion
Based on 9 articles about XERS published over the past 30 days
Neutral
Business Wire
1 day ago
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced the U.S Patent and Trademark Office has issued patent number 12,377,096 to the Company for Recorlev® (levoketoconazole) and that this patent is now listed in the publication, “Approved Drug Products with Therapeutics Equivalence Evaluations,” common.
Positive
Zacks Investment Research
2 weeks ago
Xeris Biopharma (XERS) Upgraded to Buy: Here's Why
Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Zacks Investment Research
2 weeks ago
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Neutral
Seeking Alpha
2 weeks ago
Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John P. Shannon - CEO & Director Steven M.
Positive
The Motley Fool
2 weeks ago
Xeris (XERS) Q2 Revenue Jumps 49%
Xeris (XERS) Q2 Revenue Jumps 49%
Positive
Zacks Investment Research
2 weeks ago
Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Negative
Zacks Investment Research
2 weeks ago
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
Xeris Biopharma (XERS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.1 per share a year ago.
Neutral
Business Wire
2 weeks ago
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter ended June 30, 2025, and updated its fiscal 2025 guidance. “Total revenue in the second quarter increased almost 50% year-over-year to a record $72 million, driven by increased patient demand across all three.
Neutral
Business Wire
3 weeks ago
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Thursday, August 7, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the C.
Positive
Seeking Alpha
2 months ago
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing
Compared to other biotech companies, Xeris Biopharma Holdings Inc. is a company that has successfully launched products that are already generating revenue. As the company's revenue is expected to grow significantly by 2030, the stock price may rise accordingly. Moreover, XP-8121 may serve as a catalyst for higher stock valuation.
Charts implemented using Lightweight Charts™